Pricing a large group health renewal with thin, aggregated experience
BlueShield Health is quoting for a 9,000-life corporate group with dependants. The broker has supplied only three years of aggregate loss ratios from the incumbent insurer - 71%, 84% and 96% - with no age, gender or claims-category breakdown. The workforce is ageing and 12% of members have declared chronic conditions. Medical inflation for the relevant procedures is running at 12% a year. The technical premium is ₹78 million against the incumbent's ₹62 million, and the broker has asked for a 10% discount to win the account, hinting that the group will otherwise consider self-funding. The insurer can buy 70% quota share with a 5% ceding commission and an aggregate stop-loss at 115% of expected claims. The product must be filed under the applicable product regulations, and the insurer's solvency ratio is 1.71.
1. Assess the credibility of the available data and test whether the ₹78 million technical premium is reasonable.
Read the worked answer
The data are aggregated and from another insurer, so they carry selection and definition risk, but the loss ratio trend is a strong signal.
Credibility. With 9,000 lives and a typical group claims frequency, claim counts are probably in the high hundreds to low thousands, which gives reasonable credibility for frequency but much less for severity, where a few large claims dominate. I would apply a credibility weight to the group's own experience and blend towards manual rates for the severity component, and I would treat the absence of age and category detail as a reason to load rather than to assume the mix is average - an ageing workforce with 12% chronic conditions implies deterioration.
Test of the premium. The latest loss ratio of 96% is on the current premium of ₹62 million, i.e. claims of about ₹59.5 million. Those claims were incurred in the past; claims in the rating period will be paid at inflated cost. Trending at 12% gives 96 × 1.12 ≈ 107.5%, or about ₹66.7 million of claims on the same premium basis. Add management expenses of, say, 12% and commission of 5%, plus a risk margin, and the required premium is of the order of ₹78 million. The technical premium is therefore consistent with the evidence; the 26% increase over the incumbent's rate reflects a book that is already loss-making at today's prices.
Conclusion. I would support the technical premium and resist a discount below expected cost; there is no evidence that a 10% cut is affordable.
2. Should the insurer buy the 70% quota share and the aggregate stop-loss? Show your reasoning, including the effect on the pricing decision.
Read the worked answer
Reinsurance changes the shape of the risk, not the underlying economics, and the pricing decision must be taken first.
Quota share. With an expected loss ratio trending above 100%, ceding 70% of a loss-making book simply exports most of the loss while giving up 70% of any future recovery; a 5% ceding commission is unlikely to compensate for the margin forgone. On the other hand, the quota share reduces the capital strain of a large new account, caps the downside on severity, and is useful while credibility is being established. Its value depends on the total cost of the cover relative to the capital relief it buys.
Aggregate stop-loss. This is the more valuable protection: it responds to the accumulation risk that the data cannot measure - a chronic-condition cluster or an epidemic. It should be priced against the modelled distribution of aggregate claims, not against the central estimate.
Decision framework. Price at the technical level of ₹78 million; test the retained result under a 130% and 150% loss ratio with and without the treaty; check counterparty security; and confirm the net position meets the capital plan. My recommendation would be: hold the technical price, buy the aggregate stop-loss for the first year, and use a lower quota share (or none) unless capital relief on a 9,000-life account is a binding constraint. Reinsurance must not be used to justify a discount.
3. What terms, conditions and communication approach would you recommend, and what regulatory issues arise?
Read the worked answer
Terms. Given the thin data, price the uncertainty into the structure rather than the discount: a pre-existing disease waiting period consistent with the filed product, a defined room-rent or procedure cap for the chronic-condition cohort, a co-pay for dependants, and a clear experience-rated renewal clause stating that the rate is subject to claims experience at the next renewal. Wellness and disease-management programmes for the declared chronic conditions should be offered - they reduce future cost and are defensible to the employer.
Broker and self-funding threat. The self-funding alternative should be taken seriously rather than met with a discount: offer an administration-only or a higher-deductible structure that keeps the insurer's retained risk commensurate with the price. If the group selects against the insurer on self-funding, it will do so anyway at a discount.
Regulatory issues. The product and its terms must be filed under the applicable product regulations, with the rating basis and premium revision terms documented; the premium revision clause must be disclosed to policyholders and not applied arbitrarily. Renewal terms must be applied consistently across similar groups to avoid unfair discrimination.
Communication. Put the rating basis to the broker in writing - the trending, the mix adjustment and the margin - so that the ₹78 million is seen as evidence-based, not as an opening position.